Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957787 | 0.87 | APLNR (0.50) | ADRB2APLNRCHRM2CHRM1CHRM3 | |
| SCHEMBL18182124 | 0.82 | HTR2A (0.62) | APLNRHTR2AHTR2C | |
| SCHEMBL25609396 | 0.81 | CA1 (0.59) | APLNRHTR2AHTR2CLMNAGAA | |
| SCHEMBL419377 | 0.80 | SLC6A4 (0.51) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL18256578 | 0.79 | APLNR (0.77) | APLNRMEN1KMT2AHTR2AHTR2C | |
| SCHEMBL3266399 | 0.78 | APLNR (0.49) | APLNRCHRM2MEN1KMT2AMAPK1 | |
| SCHEMBL18901130 | 0.78 | MEN1 (0.47) | ADRB2APLNRCHRM2CHRM1CHRM3 | |
| SCHEMBL12844401 | 0.78 | CHRM2 (0.56) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL7726702 | 0.77 | CHRM2 (0.55) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL13535945 | 0.77 | USP28 (0.44) | MEN1KMT2AMAPK1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | ADRB2 3001/4885APLNR 2413/4885CHRM2 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.